Century Therapeutics, Inc. (IPSC) AI Stock Analysis

Century Therapeutics, Inc. is a biotechnology company focused on advancing allogeneic cell therapies for solid tumors and hematological malignancies. The company's pipeline is led by CNTY-101, an allogeneic therapy derived from induced pluripotent stem cells (iPSCs) engineered with chimeric antigen receptors targeting CD19 for relapsed or refractory B-cell lymphoma. Additional pipeline programs include CNTY-103 targeting CD133 and EGFR for recurrent glioblastoma, CNTY-102 targeting CD19 and CD79b for B-cell malignancies, CNTY-104 for acute myeloid leukemia, and CNTY-106 for multiple myeloma. Century Therapeutics leverages its iPSC platform to develop off-the-shelf treatments designed to broaden accessibility and enhance cancer therapy efficacy.

Century Therapeutics experienced uneven revenue across recent periods, recording $1.1M in FY2021, $5.2M in FY2022, $2.2M in FY2023, and $6.6M in FY2024. Revenue rose significantly to $109.2M in FY2025, representing growth of 1556.8% and delivering a gross margin of 88.0%. Operating margin improved to -13.8% in FY2025 from -2096.5% in FY2024, while net income narrowed to -$9.6M, or -$0.06 per share. For the trailing twelve months ending June 30, 2026, revenue stood at $0, reflecting a quarterly revenue decline of 100.0% year-over-year, with trailing twelve month earnings per share of -$0.93.

As of June 30, 2026, Century Therapeutics held $119.7M in cash and short-term investments alongside total debt of $34.6M, yielding net cash of $85.1M. Shareholders' equity was $232.3M against total assets of $287.0M, supporting a current ratio of 8.28 and a debt-to-equity ratio of 0.15. Operating cash flow in FY2025 was -$103.9M, and free cash flow was -$104.7M after capital expenditures of $848,000. Over five years, the company expanded its common share count by 277.8%.

At a last close of $1.37 on October 16, 2026, Century Therapeutics had a market capitalization of $248.1M and an enterprise value of $237.6M. The stock traded at a price-to-sales ratio of 3.7x, below the median of 4.1x for its US-listed Healthcare peers. Its enterprise value-to-EBITDA ratio stood at 131.5x, well above the peer median of 12.0x, alongside a price-to-book ratio of 1.4x. Over the past year, IPSC shares gained 146.0% compared to a 16.8% return for the S&P 500, but over five years the stock generated a return of -92.9% versus 83.0% for the index.

Wall Street coverage includes 3 Strong Buy, 1 Buy, and 1 Hold rating, with no Sell or Strong Sell recommendations. The mean price target of $4.75 implies potential upside of 246.7% above the last close of $1.37. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.47 on $0 in revenue. For the following fiscal year, 4 analysts estimate an EPS of -$0.45 on $0 in revenue. The company has beaten EPS expectations in 3 of the last 4 quarters, with its next earnings report scheduled for November 12, 2026.

This page is an AI-written research summary of Century Therapeutics, Inc. (IPSC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IPSC income statement, IPSC balance sheet, IPSC key metrics, IPSC analyst forecast, IPSC chart. See the IPSC stock overview for the latest quote and news.